Observational Study About Patients Diagnosed With NAFLD

Study on the Characteristic, Therapy and Prognosis of Patients With Nonalcoholic Fatty Liver Disease

Sponsors

Lead Sponsor: Xiangya Hospital of Central South University

Source Xiangya Hospital of Central South University
Brief Summary

Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome. The largest study to date using magnetic resonance spectroscopy to quantify liver triglyceride (TG) content showed that approximately 33% of individuals have hepatic steatosis. NAFLD encompasses a continuum of histological findings that starts with steatosis that can progress to nonalcoholic steatohepatitis (NASH), which is characterized by inflammation and cell death, and eventually cirrhosis. Given the large number of individuals afflicted with this condition, there is a clear need to develop effective and safe therapies to treat NAFLD.

Detailed Description

Patients with NAFLD were recruited in the current study and divided into NAFLD group, and NASH group. The researchers will collect various clinical examination indexes of the subjects in the process of diagnosis and treatment, including but not limited to ALT, AST, TG, TC, etc. Characteristic and prognosis of patients will be recorded. The serum, feces, urine and liver (if necessary) samples of all subjects will be taken after enrollment and stored for probably testing in the future. This study has no additional intervention and treatment for subjects.

Overall Status Recruiting
Start Date 2022-04-27
Completion Date 2027-04-27
Primary Completion Date 2025-04-27
Study Type Observational
Primary Outcome
Measure Time Frame
BMI 3 weeks
alcohol intake 3 years
Enrollment 500
Condition
Eligibility

Sampling Method:

Non-Probability Sample

Criteria:

Inclusion Criteria: patients diagnosed with nonalcoholic fatty liver disease Exclusion Criteria: patients suspected of excessive alcohol consumption

Gender:

All

Minimum Age:

18 Years

Maximum Age:

75 Years

Healthy Volunteers:

Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
Yan Huang Study Director Xiangya Hospital of Central South University
Overall Contact

Last Name: Yan Huang

Phone: +86 13874854142

Email: [email protected]

Location
Facility: Status: Contact: Department of Infectious Disease, Xiangya Hospital, Central South University Yan Huang +86 13874854142 [email protected]
Location Countries

China

Verification Date

2022-05-01

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Arm Group

Label: Patients diagnosed with NAFLD

Description: All subjects will receive the currently recognized routine test of NAFLD according to their disease and no additional intervention and treatment will be added for subjects

Patient Data Undecided
Study Design Info

Observational Model: Cohort

Time Perspective: Prospective

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Nonalcoholic Fatty Liver Disease

Clinical Trials on